An old drug saves lives of COVID-19 patients

McMaster researcher Edward Mills and his team treated 739 randomly selected Brazilian COVID-19 patients with fluvoxamine, with another 733 receiving a placebo, between Jan. 15 to Aug. 6 of this year.

Every patient who received fluvoxamine during the trial was tracked for 28 days to determine their health outcomes and if they still need hospital treatment. Researchers found about a 30 per cent reduction in hospitalizations among those receiving fluvoxamine compared to those receiving the placebo.